News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Sagent Pharmaceuticals, Inc. Reports First Quarter 2011 Financi
May 13, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
SCHAUMBURG, Ill., May 13, 2011 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced financial results for the first quarter ended March 31, 2011 and provided a corporate update.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
MORE ON THIS TOPIC
Manufacturing
FDA’s first AI-focused cGMP warning letter signals new scrutiny for manufacturers
July 16, 2026
·
3 min read
·
John Potter
Psychedelics
Lilly makes up to $3.8B psychedelics play in AtaiBeckley takeover
July 16, 2026
·
2 min read
·
Tristan Manalac
IPO
Braveheart, Attovia, Vogenx keep IPOs ballooning with plans to compete in cardiometabolic, immuno
July 16, 2026
·
4 min read
·
Tristan Manalac
Psychedelics
J&J sees Spravato sales surge as psychedelic competitors loom
July 16, 2026
·
2 min read
·
Tristan Manalac
